Banque Pictet & Cie SA Increases Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Banque Pictet & Cie SA boosted its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 12.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 131,809 shares of the medical device company's stock after buying an additional 14,419 shares during the period. Banque Pictet & Cie SA's holdings in DexCom were worth $10,251,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of DXCM. Crossmark Global Holdings Inc. lifted its stake in shares of DexCom by 1.0% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company's stock valued at $1,259,000 after purchasing an additional 182 shares during the period. GPS Wealth Strategies Group LLC increased its holdings in DexCom by 13.2% in the fourth quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company's stock worth $123,000 after purchasing an additional 185 shares in the last quarter. Peterson Wealth Services lifted its stake in DexCom by 7.1% in the fourth quarter. Peterson Wealth Services now owns 3,030 shares of the medical device company's stock valued at $236,000 after buying an additional 201 shares during the period. Magnolia Capital Advisors LLC boosted its holdings in shares of DexCom by 2.6% during the 4th quarter. Magnolia Capital Advisors LLC now owns 8,198 shares of the medical device company's stock worth $638,000 after buying an additional 210 shares in the last quarter. Finally, Riverview Trust Co grew its holdings in DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock worth $31,000 after purchasing an additional 232 shares during the period. Institutional investors own 97.75% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Royal Bank of Canada decreased their price target on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating for the company in a research note on Friday, October 25th. Sanford C. Bernstein raised their price target on shares of DexCom from $82.00 to $86.00 and gave the company an "outperform" rating in a research report on Friday, October 25th. Citigroup increased their price objective on DexCom from $85.00 to $91.00 and gave the stock a "buy" rating in a research note on Wednesday, December 11th. Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and lifted their target price for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Finally, Leerink Partners lowered their price target on DexCom from $90.00 to $87.00 and set an "outperform" rating for the company in a research report on Friday, October 25th. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $99.06.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. This represents a 0.97 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the business's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares of the company's stock, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 42,342 shares of company stock worth $3,628,069 over the last 90 days. Corporate insiders own 0.30% of the company's stock.

DexCom Stock Performance

DexCom stock traded up $1.46 during midday trading on Tuesday, reaching $90.53. The stock had a trading volume of 5,693,359 shares, compared to its average volume of 3,651,431. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The firm has a market capitalization of $35.36 billion, a PE ratio of 54.21, a P/E/G ratio of 2.26 and a beta of 1.14. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The firm's 50-day moving average price is $82.65 and its 200 day moving average price is $75.62.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 17.22% and a return on equity of 31.40%. As a group, research analysts predict that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.